Federica Pergolesi
A5070139321- Cancer Immunotherapy and Biomarkers
- Diabetes Treatment and Management
- Pancreatic and Hepatic Oncology Research
- Neutropenia and Cancer Infections
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Metabolism, Diabetes, and Cancer
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Inflammatory Biomarkers in Disease Prognosis
- Immune cells in cancer
- Economic and Financial Impacts of Cancer
- Advanced Breast Cancer Therapies
- Medication Adherence and Compliance
- Gastric Cancer Management and Outcomes
- Diabetes and associated disorders
- Renal Transplantation Outcomes and Treatments
- Chronic Lymphocytic Leukemia Research
- Ferroptosis and cancer prognosis
- PARP inhibition in cancer therapy
Abstract Purpose: No evidence exists as to whether type 2 diabetes mellitus (T2DM) impairs clinical outcome from immune checkpoint inhibitors (ICI) in patients with solid tumors. Experimental Design: In a large cohort of ICI recipients treated at 21 institutions June 2014 2020, we studied on glucose-lowering medications (GLM) for T2DM had shorter overall survival (OS) and progression-free (PFS). We used targeted transcriptomics subset explore differences the tumor microenvironment (TME) or...
<p>Tumour micron-environment transcriptome analysis.</p>
<p>Kaplan-Meier survival estimates according to the receipt of no diabetes medication, other medications/insulin therapy only, and metformin (either alone or in combinations). A) Overall Survival whole cohort; patients not receiving medications: 18.9 months (95%CI: 15.9-21.6; 684 events), on only: 19.3 11.6-22.9; 48 metformin: 12.3 9.8-15.9; 100 events). B) Progression Free 8.2 7.1-9.4; 872 10.7 6.7-11.6; 61 7.9 5.1-10.1; 124 events).</p>
<p>Kaplan-Meier survival estimates according to the receipt of other diabetes medications and insulin therapy. A) Overall Survival whole cohort; patients on oral antidiabetic drugs therapy: 17.5 months (95%CI: 12.8-20.9; 82 events), not receiving therapy 17.8 15.4 – 19.7; 750 events). B) Progression Free 8.2 6.2-11.4; 106 8.1 7.1 9.2; 951 events).</p>
<p>Kaplan-Meier survival estimates according to the receipt of metformin. A) Overall Survival whole cohort; patients on metformin: 12.4 months (95%CI: 10.5-16.3; 100 events), not receiving 19.0 16.4 – 21.1; 732 events). B) Progression Free 7.9 5.3-10.1; 124 8.3 7.3 9.5; 933 events).</p>
<p>Volcano plot of differentially regulated genes identified by Nanostring analysis. The Benjamini–Hockberg P-values are correlated to fold-changes in transcripts diabetic samples (n = 11) versus non-diabetic controls 11). achieving the highest statistical significance (p value <0.05) highlighted presence corresponding gene name. Significantly downregulated transcripts: HRAS, Ras oncogene family (p=0.009); GTF3C1, transcription factor TFIIIC complex (p=0.018); LAG3, key immune...
<p>A) Heat map of the 770 transcripts analyzed with Nanostring Pancancer Immune Panel in diabetic samples (n=11) compared non-diabetic controls (n=11). B) selected differently transcripted genes.</p>
<p>Scatter diagram with regression line summarizing the linear analysis between median baseline glycaemia (used as independent variable: x-axes) and NLR dependent y-axes). 133 patients included; A significant equation was found F(1,131)= 4.09, p = 0.04) an R2 of .030. NLR: neutrophil to lymphocyte ratio.</p>
<div>Abstract<p><b>Purpose:</b> No evidence exists as to whether type 2 diabetes (T2DM) impairs clinical outcome from Immune Checkpoint Inhibitors (ICI) in patients with solid tumors. <b>Experimental Design:</b> In a large cohort of ICI recipients treated at 21 institutions June 2014 2020, we studied on glucose lowering medications (GLM) for T2DM had shorter OS and PFS. We used targeted transcriptomics subset explore differences the tumor microenvironment...
<p>Kaplan-Meier survival estimates according to the receipt of any diabetes medication. A) Overall Survival NSCLC matched cohort; patients on medication: 14.2 months (95%CI: 9.0 – 17.5; 99 events), not receiving medications: 17.5 26.6; 77 events). B) Progression Free 7.9 5.4 10.8; 113 10.1 7.7 13.8; C) Melanoma 22.9 12.0 NR; 25 NR 28.8 52 D) 11.4 4.9 23.4; 37 13.8 8.7 26.0; NR: reached; PSM: propensity score matching.</p>
<p>A) Heat map of the 770 transcripts analyzed with Nanostring Pancancer Immune Panel in diabetic samples (n=11) compared non-diabetic controls (n=11). B) selected differently transcripted genes.</p>
<p>Scatter diagram with regression line summarizing the linear analysis between median baseline glycaemia (used as independent variable: x-axes) and NLR dependent y-axes). 133 patients included; A significant equation was found F(1,131)= 4.09, p = 0.04) an R2 of .030. NLR: neutrophil to lymphocyte ratio.</p>
<p>Volcano plot of differentially regulated genes identified by Nanostring analysis. The Benjamini–Hockberg P-values are correlated to fold-changes in transcripts diabetic samples (n = 11) versus non-diabetic controls 11). achieving the highest statistical significance (p value <0.05) highlighted presence corresponding gene name. Significantly downregulated transcripts: HRAS, Ras oncogene family (p=0.009); GTF3C1, transcription factor TFIIIC complex (p=0.018); LAG3, key immune...